Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?
Eur J Cancer
.
2022 Nov:176:164-167.
doi: 10.1016/j.ejca.2022.09.006.
Epub 2022 Oct 9.
Authors
Vincenzo Di Noia
1
,
Fulvia Pimpinelli
2
,
Davide Renna
3
,
Flaminia Campo
4
,
Antonella Cosimati
5
,
Andrea Torchia
5
,
Benedetta Marcozzi
6
,
Alice Massacci
6
,
Matteo Pallocca
6
,
Raul Pellini
4
,
Aldo Morrone
7
,
Francesco Cognetti
8
Affiliations
1
Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Electronic address: vincenzo.dinoia@ifo.it.
2
Microbiology and Virology Unit, Dermatological Clinical Department, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
3
Medical Oncology 1 Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
4
Otolaryngology Head and Neck Surgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
5
Department of Clinical and Molecular Medicine, Università La Sapienza di Roma, Italy.
6
Biostatistic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
7
Scientific Direction, Dermatological Clinical Department, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
8
President of FOCE, ConFederazione Oncologi-Cardiologi-Ematologi, Rome, Italy.
PMID:
36223679
PMCID:
PMC9548024
DOI:
10.1016/j.ejca.2022.09.006
No abstract available
Publication types
Letter
MeSH terms
BNT162 Vaccine
Complementary Therapies*
Humans
Immunity, Humoral
Neoplasms*
Vaccines*
Substances
BNT162 Vaccine
Vaccines